The recent Asembia 2018 Specialty Pharmacy Summit brought 6,500 attendees to Las Vegas’ Wynn and Encore to discuss the state of the industry — a record number for the no 13-year-old conference. Attendees included executives and decision makers from pharmacies, manufacturers, wholesalers, payers and health systems, among other industry stakeholders, Florham Park, N.J.-based Asembia said.
“The growth in attendance and increasing diversity of our annual summit is a testament to the impact that specialty pharmacy has in the delivery of quality healthcare,” said Robert Irene, co-founder and president of Asembia. “Our mission is to work closely with our pharmacy customers and manufacturer partners to develop collaborative solutions for this rapidly growing marketplace. The Summit is one of the many services we offer the industry and we are thankful to receive such positive feedback about this event.”
The Asembia Specialty Pharmacy Summit included more than 80 educational seminars spanning business, clinical and financial topics, and the general session featured a panel of industry experts from OptumRx, CastiaRx, Asembia and UCB that was moderated by CNN’s David Gregory. Another featured session included a panel comprised of experts from Drug Channels Institute, J.P. Morgan Securities and IQVIA, who discussed the financial picture of specialty pharmacy and the statistical industry outlook.
The four-day Asembia Specialty Pharmacy Summit focused on four key trends shaping specialty pharmacy — increasing consumerism, emerging alliances, innovative technology and solutions for patient access — Asembia said.